MedDataX Logo

Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT ID: NCT00387972

Last Updated: 2015-04-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2/PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability of 2 doses of GW823093, compared to placebo, taken once daily in patients with Type 2 diabetes mellitus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A New Oral Treatment For Type II Diabetes Mellitus

NCT00111800

Diabetes Mellitus, Type 2
COMPLETED PHASE2

In-patient Study in Patients With Type 2 Diabetes Mellitus

NCT00259896

Type 2 Diabetes Mellitus Diabetes Mellitus, Type 2
COMPLETED PHASE1

A Study of LY3305677 in Participants With Type 2 Diabetes

NCT03928379

Diabetes Mellitus, Type 2
COMPLETED PHASE1

A Study for Participants With Type 2 Diabetes Mellitus

NCT00871572

Diabetes Mellitus, Type 2
COMPLETED PHASE2

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

NCT02119819

Diabetes Mellitus, Type 2
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

denagliptin (GW823093)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes mellitus treated with diet and exercise or oral anti-diabetic treatment
* Body mass index between 20 and 40
* Females of childbearing potential must use adequate birth control.

Exclusion Criteria

* Subjects with previous use of insulin
* Type 1 diabetes
* Uncontrolled thyroid disease
* History of drug or alcohol abuse in the past year
* Any other clinically significant disease.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trial, DM, FRCP

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Clinical Trials Call Center

Tallassee, Alabama, United States

Site Status

GSK Clinical Trials Call Center

Phoenix, Arizona, United States

Site Status

GSK Clinical Trials Call Center

Tucson, Arizona, United States

Site Status

GSK Clinical Trials Call Center

Beverly Hills, California, United States

Site Status

GSK Clinical Trials Call Center

Carmichael, California, United States

Site Status

GSK Clinical Trials Call Center

Concord, California, United States

Site Status

GSK Clinical Trials Call Center

Torrance, California, United States

Site Status

GSK Clinical Trials Call Center

Victorville, California, United States

Site Status

GSK Clinical Trials Call Center

Wilmington, Delaware, United States

Site Status

GSK Clinical Trials Call Center

Boynton Beach, Florida, United States

Site Status

GSK Clinical Trials Call Center

Clearwater, Florida, United States

Site Status

GSK Clinical Trials Call Center

Coral Gables, Florida, United States

Site Status

GSK Clinical Trials Call Center

Hialeah, Florida, United States

Site Status

GSK Clinical Trials Call Center

Hollywood, Florida, United States

Site Status

GSK Clinical Trials Call Center

Melbourne, Florida, United States

Site Status

GSK Clinical Trials Call Center

Miami, Florida, United States

Site Status

GSK Clinical Trials Call Center

Opa-locka, Florida, United States

Site Status

GSK Clinical Trials Call Center

Plantation, Florida, United States

Site Status

GSK Clinical Trials Call Center

Tampa, Florida, United States

Site Status

GSK Clinical Trials Call Center

Calhoun, Georgia, United States

Site Status

GSK Clinical Trials Call Center

Roswell, Georgia, United States

Site Status

GSK Clinical Trials Call Center

Hayden Lake, Idaho, United States

Site Status

GSK Clinical Trials Call Center

Chicago, Illinois, United States

Site Status

GSK Clinical Trials Call Center

Chicago, Illinois, United States

Site Status

GSK Clinical Trials Call Center

Lake Zurich, Illinois, United States

Site Status

GSK Clinical Trials Call Center

Watseka, Illinois, United States

Site Status

GSK Clinical Trials Call Center

Baton Rouge, Louisiana, United States

Site Status

GSK Clinical Trials Call Center

Marrero, Louisiana, United States

Site Status

GSK Clinical Trials Call Center

Oxon Hill, Maryland, United States

Site Status

GSK Clinical Trials Call Center

Detroit, Michigan, United States

Site Status

GSK Clinical Trials Call Center

City of Saint Peters, Missouri, United States

Site Status

GSK Clinical Trials Call Center

Florissant, Missouri, United States

Site Status

GSK Clinical Trials Call Center

St Louis, Missouri, United States

Site Status

GSK Clinical Trials Call Center

Las Vegas, Nevada, United States

Site Status

GSK Clinical Trials Call Center

Williamsville, New York, United States

Site Status

GSK Clinical Trials Call Center

Charlotte, North Carolina, United States

Site Status

GSK Clinical Trials Call Center

Morehead City, North Carolina, United States

Site Status

GSK Clinical Trials Call Center

Fargo, North Dakota, United States

Site Status

GSK Clinical Trials Call Center

Cincinnati, Ohio, United States

Site Status

GSK Clinical Trials Call Center

Columbus, Ohio, United States

Site Status

GSK Clinical Trials Call Center

Guthrie, Oklahoma, United States

Site Status

GSK Clinical Trials Call Center

Norman, Oklahoma, United States

Site Status

GSK Clinical Trials Call Center

Oklahoma City, Oklahoma, United States

Site Status

GSK Clinical Trials Call Center

Oklahoma City, Oklahoma, United States

Site Status

GSK Clinical Trials Call Center

Yukon, Oklahoma, United States

Site Status

GSK Clinical Trials Call Center

Eugene, Oregon, United States

Site Status

GSK Clinical Trials Call Center

Medford, Oregon, United States

Site Status

GSK Clinical Trials Call Center

Beaver Falls, Pennsylvania, United States

Site Status

GSK Clinical Trials Call Center

Fleetwood, Pennsylvania, United States

Site Status

GSK Clinical Trials Call Center

Warminster, Pennsylvania, United States

Site Status

GSK Clinical Trials Call Center

Anderson, South Carolina, United States

Site Status

GSK Clinical Trials Call Center

Chattanooga, Tennessee, United States

Site Status

GSK Clinical Trials Call Center

Johnson City, Tennessee, United States

Site Status

GSK Clinical Trials Call Center

Cleburne, Texas, United States

Site Status

GSK Clinical Trials Call Center

San Antonio, Texas, United States

Site Status

GSK Clinical Trials Call Center

Seguin, Texas, United States

Site Status

GSK Clinical Trials Call Center

Weber City, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DPB107246

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study for Patients With Type 2 Diabetes Mellitus
NCT00804986 COMPLETED PHASE2
GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin
NCT00242372 TERMINATED PHASE3
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
NCT01236404 COMPLETED PHASE1/PHASE2
GALLANT 22 Tesaglitazar vs. Placebo
NCT00252837 TERMINATED PHASE3
Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes
NCT01140893 UNKNOWN PHASE2/PHASE3
A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients
NCT01253278 COMPLETED PHASE1
In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus
NCT00354536 COMPLETED PHASE2
A Study of LY3502970 in Participants With Type 2 Diabetes
NCT04426474 COMPLETED PHASE1
A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382
NCT03341013 COMPLETED PHASE1
GALLANT 2 Tesaglitazar vs. Placebo
NCT00252772 TERMINATED PHASE3
First Time in Human Study Using GSK2330672
NCT01416324 COMPLETED PHASE1
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
NCT02460978 COMPLETED PHASE3
A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus
NCT03235219 COMPLETED PHASE1
Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus
NCT00044694 COMPLETED PHASE2
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
NCT00877890 COMPLETED PHASE3
Effect on Weight Loss of Exenatide Versus Placebo
NCT00375492 COMPLETED PHASE3
Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes
NCT03604419 COMPLETED PHASE2
Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus
NCT00085969 COMPLETED PHASE2
Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes
NCT02455076 COMPLETED PHASE4
18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes
NCT00511732 COMPLETED PHASE2
GALLANT 4 Tesaglitazar vs. Glibenclamide
NCT00255541 TERMINATED PHASE3
A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes
NCT01606397 COMPLETED PHASE1
A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM
NCT03895697 COMPLETED PHASE3
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
NCT03117998 COMPLETED PHASE2
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
NCT04143802 COMPLETED PHASE1